摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-cyclopentyl-2-(4-(4,5-dihydro-1H-imidazol-2-yl)-2-methoxyphenylamino)-5,7,7-trimethyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one | 946825-72-5

中文名称
——
中文别名
——
英文名称
9-cyclopentyl-2-(4-(4,5-dihydro-1H-imidazol-2-yl)-2-methoxyphenylamino)-5,7,7-trimethyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one
英文别名
9-cyclopentyl-2-[4-(4,5-dihydro-1H-imidazol-2-yl)-2-methoxyanilino]-5,7,7-trimethyl-8H-pyrimido[4,5-b][1,4]diazepin-6-one
9-cyclopentyl-2-(4-(4,5-dihydro-1H-imidazol-2-yl)-2-methoxyphenylamino)-5,7,7-trimethyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one化学式
CAS
946825-72-5
化学式
C25H33N7O2
mdl
——
分子量
463.583
InChiKey
HGJKCKDTBPBNKV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    34
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    95
  • 氢给体数:
    2
  • 氢受体数:
    7

文献信息

  • Dihydrodiazepines useful as inhibitors of protein kinases
    申请人:Kay David
    公开号:US20080167289A1
    公开(公告)日:2008-07-10
    The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
    本发明涉及一种作为蛋白激酶抑制剂的化合物。该发明还提供包含所述化合物的药用合适组合物,并提供使用这些组合物在治疗各种疾病、状况或障碍中的方法。该发明还提供制备本发明化合物的方法。
  • [EN] METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS<br/>[FR] PROCÉDÉS DE PRÉPARATION DE DÉRIVÉS DE PYRIMIDINE UTILES COMME INHIBITEURS DE LA PROTÉINE KINASE
    申请人:VERTEX PHARMA
    公开号:WO2011036566A1
    公开(公告)日:2011-03-31
    A method of preparing a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and claims, comprises the steps of: a) reacting a compound represented by Structural Formula (A) with FTNR1R7 under suitable conditions to form a compound represented by Structural Formula (B); and b) i) when R12 is -NO2, and R11 is -OR14: 1) cyclizing the compound represented by Structural Formula (B) under suitable cyclisation conditions to form a compound represented by Structural Formula (II); and 2) optionally reacting the compound represented by Structural Formula (II) with R9-LG2, wherein LG2 is a suitable leaving group, to form the compound represented by Structural Formula (I), wherein R8 is R9; or ii) when R12 is halogen, and R11 is -NHR13: 1) cyclizing the compound represented by Structural Formula (B) under suitable cyclisation conditions to form the compound represented by Structural Formula (I); and 2) optionally, when R13 is - H, reacting the compound produced from step b), ii), 1) with R9-LG2, wherein LG2 is a suitable leaving group, to form the compound represented by Structural Formula (I) wherein R8 is R9.
    一种制备化合物结构式(I)或其药学上可接受的盐的方法,其中结构式(I)中的变量如说明书和权利要求中所述,包括以下步骤:a)在适当的条件下,将化合物结构式(A)与FTNR1R7反应,形成化合物结构式(B);和b)i)当R12为-N02,而R11为-OR14时:1)在适当的环化条件下,使化合物结构式(B)环化形成化合物结构式(II);和2)可选择地将化合物结构式(II)与R9-LG2反应,其中LG2是适当的离去基团,形成化合物结构式(I),其中R8为R9;或ii)当R12为卤素,而R11为-NHR13时:1)在适当的环化条件下,使化合物结构式(B)环化形成化合物结构式(I);和2)可选择地,当R13为-H时,将从步骤b)ii)1)产生的化合物与R9-LG2反应,其中LG2是适当的离去基团,形成化合物结构式(I),其中R8为R9。
  • DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES
    申请人:Kay David
    公开号:US20100190765A1
    公开(公告)日:2010-07-29
    The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
    本发明涉及一种作为蛋白激酶抑制剂有用的化合物。该发明还提供包括所述化合物的药学上可接受的组合物,并且提供使用这些组合物治疗各种疾病、状况或障碍的方法。该发明还提供制备本发明化合物的方法。
  • METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS
    申请人:Charrier Jean-Damien
    公开号:US20120271045A1
    公开(公告)日:2012-10-25
    A method of preparing a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and claims. Additionally, the present invention relates to compounds of Structural Formula (I), which are useful as inhibitors of protein kinase.
    一种制备结构式(I)所代表的化合物或其药学上可接受的盐的方法,其中结构式(I)的变量如规范和权利要求所述。此外,本发明涉及结构式(I)的化合物,其作为蛋白激酶抑制剂是有用的。
  • US7622463B2
    申请人:——
    公开号:US7622463B2
    公开(公告)日:2009-11-24
查看更多

同类化合物

顺-2,4-二羟甲基-1-叔丁氧羰基氮杂环丁烷 盐酸2-环丙基吖丁啶 甲基5-甲基-2-氮杂双环[2.2.0]己-5-烯-2-羧酸酯 甲基3-(氮杂环丁烷-3-基)苯甲酸酯盐酸盐 氮杂环丁烷-3-醇 氮杂环丁烷-3-酮盐酸盐 氮杂环丁烷-3-酮; 3-氧代氮杂环丁烷 氮杂环丁烷-3-腈 氮杂环丁烷-3-甲酸甲酯盐酸盐 氮杂环丁烷-1-羧酰胺 氮杂啶-3-乙酸 氮杂啶-2-甲醇 氮杂丁烷-3-羧酸乙酯盐酸盐 氮杂丁烷-3-羧酸.盐酸盐 氮杂丁烷-1,3,3-三羧酸1-叔丁酯3-乙酯 杂氮环丁烷 替比培南杂质 哌醋甲酯杂质 吖丁啶,3-(3,4-二氯苯基)-1-甲基- 叔丁基6-羟基-2-氮杂螺[3.4]辛烷-2-羧酸酯 叔丁基6-氧代-5-氧杂-2,7-二氮杂螺[3.4]辛烷-2-羧酸盐 叔丁基 2,7-二氮杂螺[3.5]壬烷-2-甲酸酯 盐酸盐 叔-丁基8-羟基-6-硫杂-2-氮杂螺[3.4]辛烷-2-羧酸6,6-二氧化物 叔-丁基8-羟基-5-硫杂-2-氮杂螺[3.4]辛烷-2-羧酸5,5-二氧化物 叔-丁基8-氧杂-5-硫杂-2-氮杂螺[3.4]辛烷-2-羧酸5,5-二氧化物 叔-丁基5-氨基-2-氮杂螺[3.3]庚烷-2-甲酸基酯 叔-丁基5-(羟甲基)-7-氧亚基-2,6-二氮杂螺[3.4]辛烷-2-甲酸基酯 叔-丁基3-羟基-1-氧杂-6-氮杂螺[3.3]庚烷-6-羧酸酯 叔-丁基3-氨基-3-甲基-吖丁啶-1-羧酸酯 叔-丁基3-氧代-1-氧杂-6-氮杂螺[3.3]庚烷-6-羧酸酯 叔-丁基3-叔-丁基亚磺酰亚氨基吖丁啶-1-羧酸酯 叔-丁基3-[甲氧基(甲基)氨基甲酰]吖丁啶-1-羧酸酯 叔-丁基3-(异丙基氨基)吖丁啶-1-甲酸基酯 叔-丁基3-(二氟甲基)-3-羟基吖丁啶-1-甲酸基酯 叔-丁基1,6-二氮杂螺[3.3]庚烷-6-甲酸基酯盐酸 叔-丁基-8-羟基-5-氧杂-2-氮杂螺[[3.4]辛烷-2-羧酸盐 双(2,2,2-三氟乙酸) 二-1-氮杂环丁基甲酮 乙基3-亚甲基-1-吖丁啶羧酸酯 乙基2-氮杂双环[2.2.0]己-5-烯-2-羧酸酯 乙基1-叔丁氧羰基-3-氰基吖丁啶-3-羧酸酯 Sch58053苄基醚 N-甲基-3-氮杂环丁胺 N-甲基-1-甲基氮杂环丁-3-胺 N-甲基-(1-甲基氮杂环丁-3-基)甲胺 N-异丙基氮杂啶-3-胺双盐酸盐 N-boc-3-(4-氨基苯基)氮杂丁烷 N-Boc-氮杂环丁烷 N-Boc-3-羟基氮杂环丁烷 N-Boc-3-氮杂环丁烷乙酸